PF-08046054

PF-08046054 is an antibody-drug conjugate developed by Pfizer. Its target is PD-L1 (the sponsor names PD-L1). ClinicalTrials.gov describes the intervention as: Antibody Drug Conjugate Participants will receive PF-08046054, administered as an IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07144280 (A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)), in non-small-cell lung cancer. The largest, NCT07144280, plans to enrol 680 participants with primary completion expected 2028-03-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.